Refine by
Early Detection Of Prostate Cancer Equipment & Supplies
5 equipment items found
Manufactured by:Cleveland Diagnostics, Inc. based inCleveland, OHIO (USA)
IsoPSA Proceed to biopsy only when needed. IsoPSA is now included in NCCN® Prostate Cancer Early Detection Guidelines. IsoPSA can help reduce unnecessary prostate biopsies by up to 55%. Up to 75% of results from prostate biopsies performed in the US are negative for high-grade disease. By ...
Manufactured by:MicroPort Scientific Corporation based inShanghai, CHINA
Toumai™ Endoscopic Surgery Robot successfully completed its First-In-Man (FIM) trial for Robot Assisted Laparoscopic Radical Prostatectomy (RALRP) at Shanghai Oriental Hospital on November 1st 2019. Under the guidance of Academician Sun Yinghao, RALRP was provided to a 65 year old local patient, who was admitted to the hospital for early prostate cancer, the whole surgery lasted 1.5 hours. ...
Manufactured by:MDxHealth based inIrvine, CALIFORNIA (USA)
SelectMDx Helps Physicians Determine if a Patient is at Higher or Lower Risk for Prostate Cancer and Which Men Can Safely Avoid Biopsy. A non-invasive urine test (“liquid biopsy”), SelectMDx measures the expression of two mRNA cancer-related biomarkers (HOXC6 and DLX1).1 The test provides binary results that, when combined with the patient’s clinical risk factors, help the ...
Manufactured by:MDxHealth based inIrvine, CALIFORNIA (USA)
ConfirmMDx Addresses Prostate Biopsy Sampling Error and the False-Negative Biopsy Dilemma. “Rule-in” high-risk men who have had a previous negative biopsy result, may be harboring undetected cancer (a false-negative biopsy result), and therefore may benefit from a repeat biopsy and appropriate treatment. “Rule-out” otherwise cancer-free men from undergoing unnecessary ...
by:Vitanova Biomedical, Inc. (VNB) based inKerrville, TEXAS (USA)
Vitanova Biomedical’s Cancer Therapy Technology Platform is Called Light-Activated Intracellular Acidosis (LAIA). Vitanova Biomedical (VNB) has developed a proprietary energy-based technique to elicit cancer-specific intracellular acidosis. The foundation of VNB’s core technology combines three proven principles accepted in today’s cancer therapeutics: Intracellular acidosis ...